Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy

Gene Therapy

Volumn 11, Issue 2, 2004, Pages 161-169

  Shen, D H Y ^a,b   Marsee, D K ^a   Schaap, J ^a   Yang, W ^a   Cho, J Y ^a   Hinkle, G ^a   Nagaraja, H N ^a   Kloos, R T ^a   Barth, R F ^a   Jhiang, S M ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

Brain neoplasm; Radionculide therapy; Sodium iodide symporter

Indexed keywords

COTRANSPORTER; IODINE 123; IODINE 125; IODINE 131; RADIOACTIVE IODINE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM; RHENIUM COMPLEX; SODIUM IODIDE SYMPORTER;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TUMOR; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PREFERENCE; DRUG UPTAKE; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; GENETICS; GLIOMA; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MOLECULAR DYNAMICS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RADIATION RESPONSE; RAT; RAT STRAIN; SURVIVAL TIME; THYROID CELL; TIME;

ANIMALS; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; GENE THERAPY; GLIOMA; HUMANS; IODINE RADIOISOTOPES; MALE; RADIOISOTOPES; RADIOPHARMACEUTICALS; RATS; RATS, INBRED F344; RHENIUM; SYMPORTERS; TIME FACTORS; TRANSDUCTION, GENETIC;

ANIMALIA;

EID: 10744220529     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302147     Document Type: Article

References (48)

1. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996; 379: 458-460.
2. Smanik PA et al. Cloning of the human sodium Iodide symporter. Biochem Biophys Res Commun 1996; 226: 339-345.
3. 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I- symporter gene. Endocrinology 1997; 138: 4493-4496.
4. Mandell RB, Mandell LZ, Link Jr CJ. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res 1999; 59: 661-668.
5. Cho JY et al. In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Gene Therapy 2002; 9: 1139-1145.
6. La Perle KM et al. In vivo expression and function of the sodium iodide symporter following gene transfer in the MATLyLu rat model of metastatic prostate cancer. Prostate 2002; 50: 170-178.
7. Boland A et al. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res 2000; 60: 3484-3492.
8. Nakamoto Y et al. Establishment and characterization of a breast cancer cell line expressing Na+/I- symporters for radioiodide concentrator gene therapy. J Nucl Med 2000; 41: 1898-1904.
9. Haberkorn U et al. Transfer of the human NaI symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med 2001; 42: 317-325.
10. Spitzweg C et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 1999; 59: 2136-2141.
11. Carlin S et al. Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene: effect on clonogenicity in both two- and three-dimensional models. Cancer Gene Ther 2000; 7: 1529-1536.
12. Spitzweg C et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Therapy 2001; 8: 1524-1531.
13. Prados MD, Levin V. Biology and treatment of malignant glioma. Semin Oncol 2000; 27: 1-10.
14. Brandes AA, Rigon A, Monfardini S. Radiotherapy of the brain in elderly patients. Contra Eur J Cancer 2000; 36: 447-451; discussion 451-442.
15. Grau JJ, Verger E. Radiotherapy of the brain in elderly patients. Pro Eur J Cancer 2000; 36: 443-447.
16. Wheldon TE. Radiation physics and genetic targeting: new directions for radiotherapy. The Douglas Lea Lecture 1999. Phys Med Biol 2000; 45: R77-R95.
17. McDermott MW, Gutin PH, Larson DA, Sneed PK. Interstitial brachytherapy. Neurosurg Clin N Am 1990; 1: 801-824.
18. Mann BD et al. Imaging of human tumor xenografts in nude mice with radiolabeled monoclonal antibodies. Limitations of specificity due to nonspecific uptake of antibody. Cancer 1984; 54: 1318-1327.
19. Goodwin DA. Pharmacokinetics and antibodies. J Nucl Med 1987; 28: 1358-1362.
20. Goodwin DA et al. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 1988; 29: 226-234.
21. Riva P et al. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience. Cancer 1997; 80: 2733-2742.
22. Riva P et al. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study. Clin Cancer Res 1999; 5: 3275s-3280s.
23. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma - phase I and II study. Acta Oncol 1999; 38: 351-359.
24. Riva P et al. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med 2000; 27: 601-609.
25. Weber DA. MIRD: Radionuclide Data and Decay Schemes. The Society of Nuclear Medicine: New York, 1989.
26. Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 2002; 64: 259-273.
27. Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid 1997; 7: 183-187.
28. Loevinger R, Budinger TF, Watson EF. MIRD Primer For Absorbed Dose Calculation. The Society of Nuclear Medicine: New York, NY, 1991.
29. Casara D et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993; 34: 1626-1631.
30. Sherman SI. The management of metastatic differentiated thyroid carcinoma. Rev Endocr Metab Disord 2000; 1: 165-171.
31. O'Donoghue JA, Bardies M, Wheldon TE. Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. J Nucl Med 1995; 36: 1902-1909.
32. de Jong M et al. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001; 42: 1841-1846.
33. Knedlitschek G, Anderer U, Weibezahn KF, Dertinger H. Radioresistance of rat glioma cell lines cultured as multicellular spheroids. Correlation with electrical cell-to-cell-coupling. Strahlenther Onkol 1990; 166: 164-167.
34. Bloomer WD, McLaughlin WH, Adelstein SJ, Wolf AP. Therapeutic applications of Auger and alpha emitting radionuclides. Strahlentherapie 1984; 160: 755-757.
35. O'Donoghue JA, Wheldon TE. Targeted radiotherapy using Auger electron emitters. Phys Med Biol 1996; 41: 1973-1992.
36. O'Donoghue JA. Strategies for selective targeting of Auger electron emitters to tumor cells. J Nucl Med 1996; 37: 3S-6S.
37. Cunningham SH et al. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. Br J Cancer 1998; 77: 2061-2068.
38. Dadachova E, Bouzahzah B, Zuckier LS, Pestell RG. Rhenium-188 as an alternative to Iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol 2002; 29: 13-18.
39. Knapp Jr FF et al. Endovascular beta irradiation for prevention of restenosis using solution radioisotopes: pharmacologic and dosimetric properties of rhenium-188 compounds. Cardiovasc Radiat Med 1999; 1: 86-97.
40. 188Re-perrhenate in endovascular irradiation using liquid-filled balloon to prevent restenosis. Nucl Med Biol 2000; 27: 83-87.
41. Josefsson M, Grunditz T, Ohlsson T, Ekblad E. Sodium/iodide-symporter: distribution in different mammals and role in entero-thyroid circulation of iodide. Acta Physiol Scand 2002; 175: 129-137.
42. Knapp Jr FF. Rhenium-188 - a generator-derived radioisotope for cancer therapy. Cancer Biother Radiopharm 1998; 13: 337-349.
43. Knapp Jr FF et al. Reactor-produced radioisotopes from ORNL for bone pain palliation. Appl Radiat Isot 1998; 49: 309-315.
44. O'Donoghue J. Dosimetric Principles of Targeted Radiotherapy. In: Abrams PG FA (ed). Radioimmunotherapy of Cancer. Marcel Dekker: New York, 2000, pp 1-21.
45. Petrich T et al. Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter. Eur J Nucl Med Mol Imaging 2002; 29: 842-854.
46. Carlin S, Mairs RJ, Welsh P, Zalutsky MR. Sodium-iodide symporter (NIS)-mediated accumulation of [(211)At]astatide in NIS-transfected human cancer cells. Nucl Med Biol 2002; 29: 729-739.
47. Kobayashi N, Allen N, Clendenon NR, Ko LW. An improved rat brain-tumor model. J Neurosurg 1980; 53: 808-815.
48. Clendenon NR et al. Enhanced survival in a rat glioma model following BNCT. Strahlenther Onkol 1989; 165: 222-225.